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Abstract. 
Background: It remains unclear whether pediatric protocols provide a better outcome to ado-
lescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) than adult 
protocols in Taiwan. Therefore, we conducted a case-control study to compare the outcome 
events, disease-free survival (DFS), and overall survival (OS) in Taiwanese AYA patients re-
ceiving either pediatric or adult ALL protocols.   
Methods: Twenty-three Taiwanese AYA patients with ALL were retrospectively reviewed: 
eight patients received the pediatric ALL protocol modified from the Taiwan Pediatric Oncolo-
gy Group (mTPOG) regimen, and 15 were treated by using the Cancer and Leukemia Group B 
study 8811 (CALGB-8811) regimen.   
Results: The DFS rates for patients in the mTPOG and CALGB-8811 groups were 100% ver-
sus 33.3% (p = 0.016) at one year, and 100% versus 22.2% (p = 0.006) at two years, respec-
tively. The OS rates for patients in mTPOG and CALGB-8811 groups were 100% versus 37.0% 
(p = 0.013) at one year, and 100% versus 22.2% (p = 0.003) at two years, respectively. 
Conclusions: Our results suggested that the pediatric mTPOG protocol provides AYA ALL pa-
tients a better DFS and OS than the adult CALGB-8811 protocol. 
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中文摘要 
背景：對於使用兒童急性淋巴性白血病療程來治療青少年及年輕成人患者的成果，在台
灣仍是未知數。所以我們進行病例對照研究來探討使用兒童急性淋巴性白血病療程來治
療青少年及年輕成人患者其無病存活、整體存活及相關併發症。 
方法：以病例回顧的方式探討。共分析 23 例罹患急性淋巴性白血病的青少年及年輕成人
患者。其中有 8 位使用修正後的兒童急性淋巴性白血病療程(mTPOG)，另 23 位使用
CALGB 8811 治療。 
結果：使用 mTPOG 及 CALGB 8811 治療患者的 1 年無病存活率分別為 100%及 33.3% 
(p=0.016)，2 年無病存活率分別 100%及 22.2% (=0.006)。二組的 1 年整體存活率分別為
100%及 37% (p=0.013)，2 年整體存活率為 100%及 22% (p=0.003)。 
結論：我們的結果顯示罹患急性淋巴球性白血病青少年及年輕成人患者以修正後的兒童
急性淋巴性白血病療程(mTPOG)治療能提供比 CALGB 8811 治療有更高的存活率。 
 
關鍵字: 青少年及年輕成人、急性淋巴性白血病、兒童療程 
 
INTRODUCTION 
Over the past few decades, the 5-year overall sur-
vival (OS) rate for children with acute lymphoblastic 
leukemia (ALL) has reached 90% [1]. Improved 
treatment protocols and supportive care are the key 
factors contributing to this extraordinary treatment 
outcome. Unfortunately, this success has not been en-
tirely translated into adult ALL patients. The 5-year 
OS rate in ALL patients in the age group of 18 to 60 
years is only approximately 35% [2]. It is believed 
that adult ALL is a genetically different disease from 
pediatric ALL. For example, favorable genetic abnor-
malities such as hyperdiploidy > 50 or ETV6-RUNX1 
are commonly found in ALL patients between 1 to 9 
years of age [3], but less often found in adult ALL 
patients. On the contrary, the Philadelphia chromo-
some (Ph+), which is an unfavorable genetic abnor-
mality, occurs in 30% of adult patients, but is rarely 
found in children with ALL [4]. 
Improvement of the outcome of ALL in AYA pa-
tients remains one of the challenging problems in ALL 
treatment. Allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) may be one of the solutions 
providing a significant survival benefit to ALL pa-
tients between 15 and 30 years of age [5]. However, 
finding matched sibling donors for AYA patients is 
often difficult because the shortage of suitable donors 
is a problem worldwide. Instead of allo-HSCT, 
chemotherapeutic regimens modified from pediatric 
protocols could be an alternative strategy. Several tri-
als have demonstrated that treating AYA patients with 
ALL using pediatric protocols results in superior out-
comes [6,7]. However, data for treating Taiwanese 
AYA patients by using pediatric protocols are lacking.  
Therefore, we conducted a case-control study to eval-
uate if pediatric ALL protocols could provide Taiwan-
ese AYA patients with better survival benefits com-
pared to adult protocols. 
In this study, a total of 23 Taiwanese adult ALL 
patients were enrolled. Of these, eight patients re-
ceived the pediatric ALL protocol modified from Tai-
wan Pediatric Oncology Group (mTPOG) regimen [8]. 
The other 15 patients were treated by using the Cancer  
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and Leukemia Group B (CALGB) 8811 [9] or 
CALGB-8811-like regimens. The aim of this study 
was to compare the outcome events, DFS, and OS of 
both groups. 
 
PATIENTS AND METHODS 
 
Patients 
From January 2002 to December 2011, a total of 
87 Taiwanese ALL patients received treatment at our 
institution. Among them, 24 patients who were aged 
15 to 30 years were defined as AYA patients, and their 
medical records were retrospectively reviewed. A pa-
tient was excluded from the analysis because of posi-
tive results for the human immunodeficiency virus.  
Finally, a total of 23 patients were analyzed with a 
median follow-up of 363 days (range, 17-2076). 
Characteristics of the 23 patients are shown in Table 1. 
Risk classification for AYA ALL patients in this 
study was made according to the patients’ clinical 
features and cytogenetic studies [6]. Since all the pa-
tients in our cohort were more than 10 years of age, 
low-risk ALL was absent in this study. In addition, 
only patients with Ph+ were considered to harbor 
high-risk ALL. The remaining patients for whom the 
cytogenetic data were available were classified as 
having standard-risk ALL. Patients for whom cytoge-
netic data were unavailable were classified as having   
undetermined-risk ALL. This project was approved by 
the Ethics Committee of Taichung Veterans General 
Hospital. 
 
Treatment 
The mTPOG and CALGB-8811 protocols are 
compared in Table 2. Briefly, the mTPOG protocol 
consisted of two cycles of induction remission chem-
otherapy, three cycles of consolidation chemotherapy, 
four cycles of early maintenance therapy, and pro-
longed maintenance therapy until 24 months from the 
time of diagnosis. A high-dose methotrexate, cytara-
bine, or triple intrathecal therapy for central nervous 
system (CNS) prophylaxis was integrated into each 
treatment. The CALGB-8811 protocol consisted of 
one cycle of induction chemotherapy, two cycles of 
early consolidation chemotherapy followed by CNS 
prophylaxis with cranial irradiation and triple in-
trathecal therapy, one cycle of late consolidation 
chemotherapy, and prolonged maintenance therapy 
until 24 months from diagnosis. The major differences 
between the two protocols included delayed cyclo-
phosphamide and idarubicin use, higher dosage of 
L-asparaginase, and consolidation therapy with high- 
dose methotrexate and cytarabine in the mTPOG pro-
tocol. 
 
Statistical Analysis 
Outcome events included the induction remission 
rate, treatment-related mortality, and disease relapse. 
DFS was defined as the length of time from complete 
remission to the occurrence of the first relapse. OS 
was defined as the time from diagnosis to patient’s 
death. Comparison of patients’ clinical parameters 
between groups was analyzed using the Mann-  
Whitney U or Chi-square tests, whenever appropriate. 
The survival curves in each group were estimated by 
using the Kaplan-Meier method and compared using 
the log-rank test. A difference was considered signifi-
cant if p < 0.05. All statistical analyses were carried 
out using SPAS software, version 11.5 (SPAS Inc., 
Chicago, IL, USA). 
 
RESULTS 
 
Baseline Patient Characteristics 
The patients’ clinical characteristics in both groups 
are summarized in Table 3. Briefly, the average ages 
of patients at the time of diagnosis in the mTPOG and 
CALGB-8811 groups were 23.4 (range, 19-30 years) 
and 23.4 (range, 16-29 years), respectively (p = 0.975). 
Five of the 8 patients (62.5%) in the mTPOG group 
and 7 of 15 patients (46.7%) in the CALGB-8811 
group were men (p = 0.667). B-cell ALL was the major 
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Table 2. Comparisons between mTPOG and CALGB-8811 protocols 
mTPOG CALGB-8811 
Induction Phase I (4 weeks) Induction (4 weeks) 
Prednisolone 40 mg/m2, D1–21 Cyclophosphamide 1200 mg/m2, D1 
Vincristine 1.5 mg/m2, D1, 8, 15, 22 Doxorubicin 35 mg/m2, D1–3 
Idarubicin 8 mg/m2,D8, 15, 22 Vincristine 2 mg, D1, 8, 15, 22 
L-Asparaginase 6000 IU/m2, D3, 5, 7, 9, 
11, 13, 15, 17, 19, 21 
L-Asparaginase 6000 IU/m2, D5, 8, 11, 15, 
18, 22 
   Prednisolone 60 mg/m2, D1-21 
Phase II (4 weeks) Early intensification (4 weeks, repeat once) 
Cyclophosphamide 1000 mg/m2, D1 MTX (IT) 15 mg, D1 
Vincristine 1.5 mg/m2, D1, 8 Cyclophosphamide 1000 mg/m2, D1 
Cytarabine 75 mg/m2, D1-4, 8-11 6MP 60 mg/m2, D1–14 
L-Asparaginase 6000 IU/m2, D8-11 Vincristine 2 mg, D15, 22 
6MP 60 mg/m2, D1-14 L-Asparaginase 6000 IU/m2, D15, 18, 22, 
25 
TIT D1, 8 Cytarabine 75 mg/m2, D1-4, 8-11 
Consolidation I (4 weeks) CNS prophylaxis and interim maintenance 
(12 weeks) 
6MP 60 mg/m2, D15-28 Cranial irradiation 2400 cGy, D1-12 
MTX 3 g/m2 (6hrs), D1, 15 Cyclophosphamide 1000 mg/m2, D1 
Cytarabine 3 g/m2 (q12h) D2–3 6MP 60 mg/m2, D1-70 
TIT D1, 8 MTX 20 mg/m2, D36, 43, 50, 57, 
64 
   MTX (IT) 15 mg, D1, 8, 15, 22, 29 
II (4 weeks)  Late intensification (8 weeks) 
Dexamethasone 10 mg, D3, 5, 7, 9, 11, 
13, 15, 17, 19, 21 
Doxorubicin 30 mg/m2, D1, 8, 15 
Vincristine 1.5 mg/m2, D1, 8, 15 Vincristine 2 mg, D1, 8, 15 
Idarubicin 8 mg/m2, D1, 8 Dexamethasone 10 mg/m2, D1-14 
L-Asparaginase 6000 IU/m2, D3, 5, 7, 9, 
11, 13, 15, 17, 19, 21 
Cyclophosphamide 1000 mg/m2, D29 
TIT D1 Cytarabine 75 mg/m2, D29-32, 36-39 
III (4 weeks)    
Cyclophosphamide 1000 mg/m2, D1    
Vincristine 1.5 mg/m2, D1, 8    
Cytarabine 75 mg/m2, D3-6, 10-13    
6MP 60 mg/m2, D1-14    
TIT D1    
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Maintenance I (2 weeks) Prolonged maintenance (every 4 weeks, until 
24 months from diagnosis) 
Etoposide 150 mg/m2, D1 Vincristine 2 mg, D1 
Cyclophosphamide 300 mg/m2, D1 Prednisolone 60 mg/m2, D1-5 
MTX 20 mg/m2, D1, 8 MTX 20 mg/m2, D1, 8, 15, 22 
6MP 60 mg/m2, D8-14 6MP 60 mg/m2, D1-28 
II (2 weeks)    
MTX 20 mg/m2, D1, 8    
Cytarabine 300 mg/m2, D1    
6MP 60 mg/m2, D8-14  
III (2 weeks)    
Vincristine 1.5 mg/m2, D1    
Dexamethasone 6 mg/m2, 7days    
L-Asparaginase 12000 IU/m2, D1  
6MP 60 mg/m2, D8-14    
IV (2 weeks)    
MTX 3 g/m2, D1    
Cytarabine 3 g/m2 (q12h), D2    
L-Asparaginase 6000 IU/m2, D1-4  
Prolonged maintenance (every 4 weeks, until 24 months from diagnosis)   
  Vincristine 2 mg, D1    
  Prednisolone 60 mg/m2, D1-5    
  MTX 20 mg/m2, D1, 8, 15, 22    
  6MP 60 mg/m2, D1-28     
mTPOG: modified Taiwan Pediatric Oncology Group; CALGB-8811: Cancer and Leukemia Group B 8811; MTX: methotrexate; 
6MP: 6-Mercaptopurine; TIT: Triple intrathecal chemotherapy; IT: Intrathecal chemotherapy; CNS: Central nervous system 
 
 
histological diagnosis in both mTPOG (7/8, 87.5%) 
and CALGB-8811 (14/15, 93.3%) groups (p = 1.000). 
 
Outcome Events 
All the eight patients in the mTPOG group com-
pleted their first induction remission therapy and 
achieved complete remission (100%), while only 9 of 
15 (60%) patients in the CALGB-8811 group achieved 
complete remission. Despite the lack of statistical sig-
nificance, this result suggested that AYA ALL patients 
who received mTPOG induction therapy were made 
likely to achieve complete remission rates better than 
those who received the CALGB-8811 protocol (p = 
0.0582). We further analyzed the causes of induction 
failure in patients in the CALGB-8811 group. Among 
the six patients in the CALGB-8811 group who did 
not achieve complete remission after induction remis-
sion chemotherapy, three died from sepsis during the 
neutropenic period and three had refractory ALL. 
 
Survival Analysis  
All the patients in the mTPOG group survived and 
showed complete remission during the follow-up pe-
riod. However, an ALL relapse occurred in eight of the 
nine patients in the CALGB-8811 group who achieved 
complete remission after induction chemotherapy. 
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Table 3. Comparison of patients’ characteristics between mTPOG and CALGB-8811 groups 
  All patients (n = 23) mTPOG (n = 8) CALGB-8811 (n = 15) p value 
Gender (female/male) 11/12 3/5 8/7 0.667† 
Mean age (years) 23.2 23.38 23.4 0.975‡ 
B-cell ALL (%) 21 (91.3) 7 (87.5) 14 (93.3) 1.000† 
Leucocyte (cumm, median ± SD) 7900 ± 13416 7100 ± 180268 13880 ± 42865 1.000‡ 
Risk classification    0.019† 
High risk 2 0 2  
Standard risk 14 8 6  
Undetermined 7 0 7  
mTPOG: modified Taiwan Pediatric Group; CALGB-8811: Cancer and Leukemia Group B-8811; ALL: acute lymphoblastic 
leukemia; CR: complete remission; DFS: disease-free survival; OS: overall survival 
†p for Chi-squared test; ‡p for Mann-Whitney U-test 
 
 
We next analyzed the DFS and OS in our study 
cohort, and the results are shown in Figure 1. The DFS 
rates for patients in the mTPOG and CALGB-8811 
groups were 100% versus 33.3% (p = 0.016) at one 
year, and 100% versus 22.2% (p = 0.006) at two years, 
respectively. Patients who received the mTPOG pro-
tocol displayed a better DFS than those who received 
the CALGB-8811 protocol (Figure 1A). The OS rates 
for patients in the mTPOG and CALGB-8811 groups 
were 100% versus 37.0% (p = 0.013) at one year, and 
100% versus 22.2% (p = 0.003) at two years, respec-
tively, suggesting that the mTPOG protocol provided 
AYA ALL patients with a better OS rate than the 
CALGB-8811 protocol (Figure 1B). 
   
It is Presumed that a Higher Dose of 
L-asparaginase could Possibly Contribute 
to a Better Outcome in AYA Patients 
with ALL 
Our study was in agreement with previous studies 
demonstrating that increased dosage of L-asparaginase 
might improve ALL patients’ survival [10,11]. The 
recommended L-asparaginase dose in the mTPOG and 
CALGB-8811 protocols are 180000 IU/m2 and 60000 
IU/m2, respectively. The L-asparaginase dose used to 
treat patients in the mTPOG and CALGB-8811 groups 
were 138055 ± 71843 IU/m2 and 26315 ± 25803 
IU/m2 (median ± standard error), respectively (p = 
0.002). 
To understand if a higher dose of L-asparaginase 
could possibly result in both better treatment response 
and survival benefit in AYA patients with ALL, we 
compared the L-asparaginase dose in our cohort on the 
basis of patient outcome, and it was shown that the 
accumulative L-asparaginase dose was 111111 ± 
72529 IU/m2 for AYA ALL patients who remained in 
complete remission during the follow-up (n = 9). 
However, for patients who had a relapse (n = 8), it 
was 21981 ± 26484 IU/m2 (median ± standard error) 
(p = 0.006). In terms of the association between sur-
vival benefits and L-asparaginase dosage, we found 
that the accumulative L-asparaginase dose for patients 
who were alive during the follow-up (n=12) was 
66458 ± 71785 IU/m2, while it was only 21164 ± 
28821 IU/m2 (median ± standard error) for patients 
who died (n=11, p=0.013). 
 
Adverse Effects and Toxicities 
As described previously, three patients in the 
CALGB-8811 group died of sepsis during the neutro-
penic period (3/15, 20.0%). In addition, as thrombosis, 
pancreatitis, hyperglycemia, hypertriglyceridemia, and  
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Figure 1. The disease-free survival (DFS) and overall survival (OS) in adolescent and young adult (AYA) patients 
with acute lymphoblastic leukemia (ALL) were analyzed by using the Kaplan-Meier method.  (A) The 
DFS rates for patients in the mTPOG and CALGB-8811 groups were 100% versus 33.3% (p = 0.016) at 
one year, and 100% versus 22.2% (p = 0.006) at two years, respectively.  Patients who received the 
mTPOG protocol showed better DFS as compared to those who received the CALGB-8811 protocol. (B) 
The OS rates for patients in the mTPOG and CALGB-8811 groups were 100% versus 37.0% (p = 0.013) 
at one year, and 100% versus 22.2% (p = 0.003) at two years, respectively, suggesting that the mTPOG 
protocol provided AYA ALL patients with a better OS than the CALGB-8811 protocol 
 
 
hepatotoxicity could be serious concerns in patients 
receiving L-asparaginase treatment [12], we analyzed 
the adverse effects of this treatment. We found that 
only one patient in our cohort suffered from a life- 
threatening adverse effect, namely, acute pancreatitis 
complicated with diabetic ketoacidosis. All the other 
patients tolerated L-asparaginase treatment, without 
any adverse effects. 
 
DISCUSSION  
In the current study, we presented the results of 
our study involving the use of the pediatric protocol 
for the treatment of Taiwanese AYA ALL patients. At-
tempts to use pediatric regimens to treat AYA patients 
with ALL began in early 2000. One of the pilot studies 
conducted by Boissel et al. [13] compared the com-
plete remission and survival rates of French ALL pa-
tients aged 15-20, who were treated with the pediatric 
FRALLE-93 or the adult LALA-94 protocols. In their 
study, a total of 177 patients were retrospectively re-
viewed. Patients who received the FRALLE-93 pro-
tocol showed an improved complete response rate 
(94% versus 83%, p = 0.04), an estimated 5-year 
event-free survival (67% versus 41%, p < 0.001), and 
an overall survival (78% versus 45%, p < 0.001). 
Several further studies [14,15] confirmed such results, 
suggesting that pediatric protocols can provide AYA 
patients with ALL with better survival benefits than 
adult protocols. Factors that are likely to contribute to 
the superior outcome with pediatric ALL protocols 
include shorter time intervals between cycles, use of 
additional non-myelosuppressive drugs, delayed in-
tensification and maintenance phases, and early and 
enhanced CNS-directed therapy [16]. 
Based on the criteria mentioned above, we de-
signed the mTPOG protocol. Compared to patients in 
the CALGB-8811 group, patients in the mTPOG 
group displayed both superior 2-year DFS and OS 
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rates. There are several possible explanations for these 
survival benefits. First, the treatment-free period was 
only 1 to 2 weeks between cycles in the mTPOG pro-
tocol. To further shorten the drug-free interval, 
6-mercaptopurine was routinely used during the 
drug-free interval. Additionally, in the mTPOG proto-
col, cyclophosphamide was generally not introduced 
until phase II induction remission therapy, which 
could possibly prevent prolonged myelosuppression 
following phase I induction remission therapy. This 
treatment regimen showed preliminarily clinical bene-
fits. Among the 15 patients in the CALGB-8811 group, 
three died of sepsis before neutrophil recovery during 
their phase I induction therapy. On the contrary, no 
treatment-related mortalities occurred in the mTPOG 
group. Moreover, all the patients in the mTPOG group 
achieved complete remission after treatment, while in 
the CALGB-8811 group, only 9 of 15 achieved com-
plete remission, suggesting that delayed introduction 
of the myelosuppressive drugs to AYA patients with 
ALL was not only therapeutically but also less toxic. 
An increased dosage of L-asparaginase might be 
another important factor underlying the improved 
outcome with the mTPOG regimen. The benefits of an 
increased dosage of L-asparaginase in ALL treatment 
have been widely discussed. A study conducted by 
Rijneveld et al. [17] showed that when adult ALL pa-
tients up to the age of 40 were treated by using a pedi-
atric regimen consisting of an increased dosage of 
L-asparaginase, steroids, methotrexate, vincristine, and 
allo-HSCT, they experienced a 2-year event-free and 
OS rates of 66% and 72%, respectively. Our study 
reiterated the importance of L-asparaginase usage; its 
dosage was higher in AYA ALL patients who experi-
enced both better treatment response (p = 0.002) and 
survival outcome (p = 0.007). More importantly,  
because only 1 patient in our cohort experienced 
life-threatening acute pancreatitis and diabetic ke-
toacidosis, we proposed that increased dosage of 
L-asparaginase would be safe as long as the patients 
were closely monitored for coagulopathy, liver func-
tion impairment, elevated blood sugar and occurrence 
of acute pancreatitis. 
In terms of CNS-directed therapy, in contrast to 
cranial irradiation used in the CALGB-8811 protocol, 
patients in the mTPOG group were treated with both 
triple intrathecal chemotherapy and high-dose metho-
trexate combined with cytarabine chemotherapy. Alt-
hough cranial irradiation is an effective prevention 
strategy against CNS relapse in ALL, its efficacy is 
frequently offset by substantial toxicity [18]. Fortu-
nately, CNS relapse did not occur in any of our pa-
tients in the mTPOG group, suggesting that high-dose 
systemic methotrexate and cytarabine combined with 
triple intrathecal chemotherapy could be as effective 
as cranial irradiation for the prevention of ALL CNS 
relapse, which was possibly translate into superior OS 
in patients who received mTPOG protocol. 
The major limitations of our study were the retro-
spective study design and the small study cohort. In 
addition, all the patients in the mTPOG group had 
standard-risk ALL, but two patients in the CALGB- 
8811 group had high-risk ALL due to Ph+. Moreover, 
cytogenetic data were unavailable for seven patients in 
the CALGB-8811 group, resulting in imprecise risk 
classification. These findings suggested that the im-
proved DFS and OS in the mTPOG group could par-
tially be attributed to patients carrying a lower risk of 
ALL (p = 0.019), rather than the efficacy of the pro-
tocol alone. Besides, the role of allo-HSCT in AYA 
patients with ALL was not evaluated in this study de-
spite its recommended application in the first com-
plete remission phase in high-risk patients [19]. In fact, 
in the CALGB-8811 group, four patients eventually 
received allo-HSCT, and three of them survived with 
complete remission disease status. 
In summary, our study demonstrated as compared 
to the CALGB-8811 protocol, the mTPOG protocol 
provided improved DFS and OS rates in Taiwanese 
AYA ALL patients, especially those with standard-risk 
ALL. This improved outcome could possibly result 
from reduced treatment-related mortality arising from 
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delayed introduction of myelosuppressive drugs, 
while the increased dosage of L-asparaginase could 
explain the enhanced treatment response. Studies us-
ing randomized-control design, along with larger co-
horts focusing on Asian AYA ALL patients are urgent-
ly required to ensure improved prospects for future 
treatment strategies. 
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